858 Therapeutics Email Format

Biotechnology ResearchCalifornia, United States11-50 Employees

858 Therapeutics is a San Diego-based biotechnology company focused on drug discovery, developing a portfolio of small molecule therapies that target novel cancer pathways. Drawing on expertise in epigenetics, single-cell genomics, and innate immunity, the organization seeks to address cancers that resist existing treatments. Its work draws on these scientific strengths to advance oncology targets, and the company is headquartered in San Diego, California, with laboratory operations in San Diego and New York City to access scientific talent on both coasts. The organization engages in collaborations to bolster its discovery efforts and maintain proximity to leading researchers.

The company has pursued external collaborations, including a 2024 partnership with OpenBench to accelerate small molecule drug discovery. It is developing ETX-19477, a PARG inhibitor, and has indicated that initial data from the first-in-human Phase 1/2 trial will be presented at the 2026 ASCO Annual Meeting.

Sign up for free to view info

Company overview Employee directory